Healthcare
Live Price
Offline$4.01
+1.78% today
1Y Change
-21.98%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
AVITA Medical, Inc. (RCEL) is a Healthcare stock with a market cap of $110.00M and listed on NASDAQ. The stock last traded around $4.01 and down 22.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +11.5%, EPS growth of +27.2%, a dividend yield of 0.0%. What stands out right now is revenue +11.5%, EPS +27.2%, free cash flow +46.5% with operating margin -59.4% and ROIC 676.8%. Valuation is more restrained than many high-expectation growth names at price/sales 1.5. Stock Foundry combines RCEL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RCEL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RCEL Max Drawdown
-51.63%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RCEL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$33.0M
-4.1% YoY
FY Net Income
-$25.1M
+5.7% YoY
Free Cash Flow
-$18.5M
+5.6% YoY
Revenue Growth
+11.5%
EPS Growth
+27.2%
Gross Margin
82.1%
Net Margin
-67.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 72M | 64M | 50M | 34M | 33M |
| Gross Profit | 59M | 55M | 42M | 28M | 27M |
| Operating Income | -42M | -57M | -43M | -28M | -25M |
| EBITDA | -40M | -55M | -34M | -26M | -24M |
| Net Income | -49M | -62M | -35M | -27M | -25M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 10M | 14M | 22M | 18M | 56M |
| Total Assets | 56M | 80M | 112M | 98M | 116M |
| Total Liabilities | 73M | 75M | 63M | 14M | 11M |
| Shareholder Equity | -17M | 4M | 49M | 85M | 105M |
| Total Debt | 2M | 46M | 42M | 918K | 2M |
| Net Debt | -8M | 32M | 20M | -17M | -54M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
18M
+5.5% YoY
Capital Expenditures
487K
+7.2% YoY
Free Cash Flow
19M
+5.6% YoY
Key ratios
Gross Margin
82.1%
Operating Margin
-59.4%
Net Margin
-67.8%
ROE
476.6%
Debt / Equity
-0.13x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.